StockData
PMGC Holdings Inc. logo

PMGC Holdings Inc. (ELAB) company profile

ELABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/3095% below fair value
$1.48−0.18 (-10.84%)

Close on Nov 17, 2026Market cap $1.32MP/E –Yield –

About PMGC

Pharmaceutical Preparations, SIC 2834

PMGC Holdings Inc. is a diversified holding company that manages and operates a portfolio of four wholly owned operating subsidiaries. Its subsidiary Northstrive Biosciences develops biopharmaceutical and aesthetic medicine candidates, focusing on engineered probiotic therapies designed to preserve muscle mass during weight loss treatment. Subsidiary Pacific Sun Packaging designs and supplies custom-engineered protective packaging solutions, including trays and carriers for delicate computer processors, memory modules, storage drives, and optical transceivers. Subsidiary AGA Precision Systems operates as a specialized computer numerical control machine shop providing high-tolerance milling, turning, and mold manufacturing for complex metals such as titanium and Inconel. PMGC Capital operates as an investment subsidiary engaged in multi-strategy investing and lending.

The company serves aerospace manufacturers, defense contractors, industrial equipment producers, and over 300 commercial electronics customers across North America, including data center operators and original equipment manufacturers. PMGC Holdings maintains its principal executive office in Newport Beach, California, with manufacturing facilities in California.

Summary of the business section of PMGC's latest annual report, written by StockData.

Company profile

Company

Legal name
PMGC Holdings Inc.
Headquarters
Newport Beach, CA
Address
120 Newport Center Drive 92660
Phone
(888) 445-4886
Employees
32, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
HTL International, LLC, Houston

Stock & identifiers

Ticker
ELAB
Exchange
Nasdaq
IPO date
Nov 22, 2023
Shares outstanding
8M, Aug 14, 2026
Public float
$101.00M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-10 reverse, Aug 21, 2026; 1-for-6 reverse, Mar 10, 2026; 1-for-4 reverse, Jan 6, 2026; 1-for-1400 reverse, Mar 28, 2025; 1-for-7 reverse, Mar 10, 2025; 1-for-200 reverse, Nov 27, 2024
SEC CIK
1840563
CUSIP
28622K302
ISIN
US28622K3023
FIGI
BBG01JLC7VG4
Share class FIGI
BBG01JLC7VH3
EIN
85-1399981

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Graydon BenslerChief Executive Officer, Director4,019,557
Jeffrey ParryDirector3
George KovalyovDirector0
Juliana DaleyDirector1
Lichti BraedenDirector3,336,437

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusTotalvs. prior year
Graydon Bensler
Non-Employee, Non-Executive Chief Executive Officer, Chief Financial Officer and Director
$262.00K$435.80K$697.80K+78%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 22, 2023
Offer price
$4.00
Securities offered
1,500,000
Gross proceeds
$6.00M
Exchange
Nasdaq
First trading day
Nov 21, 2023
First-day close
$3.40-15.0%
Lock-up ends (est.)
May 19, 2024

“The initial public offering price of our shares of Common Stock is $4.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of the date of this Annual Report, we have 32 full-time employees and 2 part-time employee.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?